Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 4.23B P/E - EPS this Y 25.00% Ern Qtrly Grth -
Income -479.45M Forward P/E -9.13 EPS next Y 9.30% 50D Avg Chg 2.00%
Sales 563.95M PEG -0.20 EPS past 5Y - 200D Avg Chg 7.00%
Dividend N/A Price/Book N/A EPS next 5Y 27.80% 52W High Chg -42.00%
Recommedations 1.80 Quick Ratio 6.11 Shares Outstanding 121.71M 52W Low Chg 75.00%
Insider Own 4.15% ROA -17.64% Shares Float 109.64M Beta 0.90
Inst Own 93.49% ROE -438.13% Shares Shorted/Prior 9.56M/7.76M Price 36.14
Gross Margin 59.74% Profit Margin -85.02% Avg. Volume 2,181,495 Target Price 37.53
Oper. Margin -73.42% Earnings Date May 9 Volume 1,897,454 Change -4.88%
About Guardant Health, Inc.

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Guardant Health, Inc. News
04/22/24 Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
04/22/24 FDA Advisory Panel Review of Guardant Health’s Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23
04/18/24 Guardant Health to Report First Quarter 2024 Financial Results on May 9, 2024
04/03/24 Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting
04/02/24 Exact Sciences, A Cathie Wood Stock, Surges As Rival Colon Cancer Test Pales
04/01/24 Better Than ChatGPT? New Super AI Bot Says Buy These 3 Stocks.
03/30/24 20 Foods To Reduce Cancer Risk
03/13/24 A blood test for colon cancer performed well in a study, expanding options for screening
03/13/24 Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine
03/06/24 Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/01/24 New Survey: Patients and Physicians Overwhelmingly Agree Blood Tests Could Help Close the Colorectal Cancer Screening Gap
02/28/24 21 Countries that Have the Highest Rates of Cancer Deaths
02/23/24 Guardant Health, Inc. (NASDAQ:GH) Q4 2023 Earnings Call Transcript
02/23/24 Guardant Health Insiders Added US$5.05m Of Stock To Their Holdings
02/22/24 Guardant Health (GH) Reports Q4 Earnings: What Key Metrics Have to Say
02/22/24 Guardant Health (GH) Reports Q4 Loss, Tops Revenue Estimates
02/22/24 Guardant Health Inc (GH) Reports 25% Revenue Growth in Full Year 2023
02/22/24 Guardant Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook
02/22/24 Wall Street Analysts Think Guardant Health (GH) Could Surge 109.89%: Read This Before Placing a Bet
02/16/24 15 Best Hospitals for Cancer Treatment in the US
GH Chatroom

User Image Cutlass Posted - 1 day ago

$GH Nice quiet 4%+ day - ✔

User Image nycpupster Posted - 1 day ago

$GH low risk setup

User Image G101SPM Posted - 1 day ago

$GH $17.44 bid. DAC $18.22 (3.14.24). EXIT $30.00 - midterm. NEWS: Guardant Health resumed with a Buy at Craig Hallum; tgt $28 .

User Image Alon_R Posted - 2 days ago

$GH May 23rd - formality of blood test that will be able to track cancer in it earliest stage. First, colorectal. Afterwards, other types. It's more meaningful than Corona Cerum by Pfizer back then i think, because it is not periodically as the Corona, but basically very important globally for the entire humanity, constantly, till science will find for human beings a scientific/technological solution for Cancer. That's the essence of May 23rd formality. Global importance.

User Image Metal_Health Posted - 2 days ago

$GH anybody still shorting when the SHIELD FDA approval comes though and it will.

User Image burningmoneyagain Posted - 3 days ago

$GH I have added an eye raising flow, and the chart. I know it's been beat up a bit, but this might be worth a look. You all be the judge. It's about 500K of PREM. Good luck.

User Image Academia Posted - 3 days ago

$GH Long and Strong 💪 here wirh $17+ average, will add lower, will sell $150.00

User Image Greer1978 Posted - 3 days ago

$GH $19+ open tomorrow $$$

User Image Alon_R Posted - 3 days ago

$GH How huge this statement is when fulfilled? Take current value X 50 and it's a fair possibility in a few years. We can't tell the future precisely and for that reason I've added the word, possibility. Starting with colorectal cancer early detection May 23th, which is already a huge milestone and very important news to hundreds of million males globally. But it won't end there because Guardant said it's gonna expand it to other cancer types. We are talking of the entire humanity. It's a huge event that I can compare to Corona Cerum developed by Pfizer that leaped their value to the sky... Only one "tiny" difference => Corona drug was good for a year or two... but Guardant development of early detection for cancer, could be good as long as Cancerous diseases existed (and believe me I would give up on any possible gain here if we had the scientific ability to get rid of cancer right to begin with)

User Image Greer1978 Posted - 3 days ago

$GH going over $22 tomorrow, $30 by friday$$$$$$, heading to $100 ++++ in short order$$$$

User Image Dutchman77 Posted - 3 days ago

$GH what’s the news here? Ty

User Image G101SPM Posted - 3 days ago

$GH $17.31 bid. DAC $18.22 (3.14.24). EXIT $30.00. UPDATE: Announces the Molecular and Clinical Genetics Panel of the U.S. FDA Medical Devices Advisory Committee is scheduled to review the premarket approval application for the company's Shield blood test for colorectal cancer screening on Thursday, May 23, 2024.

User Image Listener2307 Posted - 3 days ago

@thingkfast I'd love to know what causes these bear traps, but I honestly have no idea. On 3/28, it shot from 18.20 to 20.60. Then two days later it went from 20.75 to 22.30. Pretty scary for us shorts. There have been several other upward bumps, of course, but the fundamentals don't support a higher price. $GH trades at 13X Book. Well developed medical companies sell at 5X book. Or less.

User Image RonIsWrong Posted - 3 days ago

$GH @IsabellaDC

User Image Alon_R Posted - 3 days ago

$GH I'm in! Couldn't ignore the news in all the reagrard to the life changing/saving meaning for so many millions globally, in all the regard to Shield blood test for colorectal cancer screening on May 23. And financially, that's an event that may aid the company to leap upto worth of 5-10 times it current value. It's a biggie. GL to all involved.

User Image Listener2307 Posted - 3 days ago

$GH Today's (Monday) action is a Bear Trap, I think. There is no unexpected news and no developments. Trend will probably continue downward.

User Image IsabellaDC Posted - 3 days ago

Swing candidates scan. No studies done. Just spitting out what the scanners gave: $NGVT $DAVE $GH $SE $TROX and so on.

User Image Kaptinmorgan4 Posted - 3 days ago

$GH https://finance.yahoo.com/news/fda-advisory-panel-review-guardant-125200837.html

User Image TradeTalkMedia Posted - 3 days ago

$GH coming in after all time lows. ER 5/9.

User Image Stock_Titan Posted - 3 days ago

$GH FDA Advisory Panel Review of Guardant Health’s Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23 https://www.stocktitan.net/news/GH/fda-advisory-panel-review-of-guardant-health-s-shield-blood-test-to-runb7sarmbtr.html

User Image Listener2307 Posted - 6 days ago

$GH Still the same pattern, if it can be called that: We see 3 or sometimes 4 Red candles, and then 2 or 3 Green ones. The Green ones this time were very weak.

User Image Stock_Titan Posted - 1 week ago

$GH Guardant Health to Report First Quarter 2024 Financial Results on May 9, 2024 https://www.stocktitan.net/news/GH/guardant-health-to-report-first-quarter-2024-financial-results-on-op7h68i0wg4d.html

User Image Listener2307 Posted - 1 week ago

$GH I sold my April 20Ps for $4.00. I made some money on them, but not much. Made some money last month, too, on the March 20Ps - again, not much. Still holding my short - 1750 shares.

User Image Willieberich Posted - 1 week ago

$GH shorts look like they're playing with themselves...

User Image arribaStocktrading Posted - 1 week ago

$GH The sheer lack of volume tells you that the Market Makers are the ones driving the price down and not people selling. This is not a functioning market. It's a bullshit market where collusion and corruption are everything and investors simply don't have a say.

User Image Andreas36 Posted - 1 week ago

$GH a slowly improving balance sheet and overall progress being made, but the optimal word there is 'slowly'.

User Image Stonkey Posted - 1 week ago

$GH Hopeless POS.....

User Image Cutlass Posted - 1 week ago

$GH Added today

User Image Willieberich Posted - 1 week ago

$GH I opened a separate position just to swing trade .I have my long. And I'll trade this for more shares..

User Image TG770 Posted - 1 week ago

$GH A new 52 weeks low 🤦

Analyst Ratings
Goldman Sachs Buy Apr 15, 24
Guggenheim Neutral Apr 5, 24
Piper Sandler Overweight Feb 26, 24
JP Morgan Overweight Feb 23, 24
Canaccord Genuity Buy Feb 23, 24
Goldman Sachs Buy Jan 30, 24
Goldman Sachs Buy Jan 29, 24
Guggenheim Neutral Dec 14, 23
Wolfe Research Peer Perform Dec 13, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Chudova Darya Chief Technology Off.. Chief Technology Officer Jan 16 Option 8.80 6,626 58,309 35,305 01/16/24
Joyce Meghan V. Director Director Dec 04 Sell 26.34 100 2,634 4,422 12/05/23
Joyce Meghan V. Director Director Dec 04 Option 0 66 4,522 12/05/23
Kalia Kumud Chief Information Of.. Chief Information Officer Dec 01 Sell 26.37 5,800 152,946 5,926 12/04/23
Kalia Kumud Chief Information Of.. Chief Information Officer Dec 01 Option 0 710 12,079 12/04/23
Chudova Darya Chief Technology Off.. Chief Technology Officer Nov 15 Option 8.80 4,000 35,200 27,683 11/16/23
Chudova Darya Chief Technology Off.. Chief Technology Officer Sep 28 Option 8.80 4,500 39,600 20,180 09/29/23
Kalia Kumud Chief Information Of.. Chief Information Officer Sep 12 Sell 32.59 2,125 69,254 7,813 09/13/23
Joyce Meghan V. Director Director Sep 04 Sell 35.01 100 3,501 4,323 09/06/23
Joyce Meghan V. Director Director Sep 04 Option 0 66 4,423 09/06/23
Joyce Meghan V. Director Director Jun 14 Sell 37.55 2,766 103,863 4,224 06/16/23
Joyce Meghan V. Director Director Jun 14 Option 0 5,531 6,990 06/16/23
Kalia Kumud Chief Information Of.. Chief Information Officer Jun 09 Buy 32.73 2,981 97,568 5,193 06/13/23
Eltoukhy Helmy Co-Chief Executive O.. Co-Chief Executive Officer Mar 14 Buy 26.24 93,052 2,441,684 2,049,238 03/16/23
Talasaz AmirAli Co-Chief Executive O.. Co-Chief Executive Officer Mar 13 Buy 25.74 97,000 2,496,780 24,250 03/15/23
Merrill Amelia SVP, People SVP, People Aug 11 Option 4.18 5,000 20,900 29,208 08/15/22
Merrill Amelia SVP, People SVP, People Aug 11 Sell 53.85 9,000 484,650 20,208 08/15/22
MERESMAN STANLEY J Director Director Mar 10 Option 5.94 4,934 29,308 8,993 03/14/22
MERESMAN STANLEY J Director Director Mar 10 Sell 58.74 4,934 289,823 4,059 03/14/22
MERESMAN STANLEY J Director Director Jan 10 Option 5.94 4,934 29,308 8,993 01/12/22
MERESMAN STANLEY J Director Director Jan 10 Sell 86.08 4,934 424,719 4,059 01/12/22
MERESMAN STANLEY J Director Director Dec 10 Option 5.94 4,934 29,308 8,993 12/14/21
MERESMAN STANLEY J Director Director Dec 10 Sell 95.59 4,934 471,641 4,059 12/14/21
Eltoukhy Helmy Co-Chief Executive O.. Co-Chief Executive Officer Nov 19 Buy 95.78 104,500 10,009,010 1,956,186 11/23/21
Talasaz AmirAli Co-Chief Executive O.. Co-Chief Executive Officer Nov 19 Buy 95.8 104,500 10,011,100 1,853,845 11/23/21
MERESMAN STANLEY J Director Director Oct 11 Option 5.94 4,934 29,308 8,993 10/13/21
MERESMAN STANLEY J Director Director Oct 11 Sell 103.59 4,934 511,113 4,059 10/13/21
MERESMAN STANLEY J Director Director May 12 Option 5.94 4,934 29,308 8,993 05/12/21
MERESMAN STANLEY J Director Director May 12 Sell 133.01 4,934 656,271 4,059 05/12/21
CLARK IAN T Director Director Apr 28 Option 4.18 538 2,249 5,181 04/28/21
CLARK IAN T Director Director Apr 28 Sell 159.92 538 86,037 4,643 04/28/21
Eltoukhy Helmy Chief Executive Offi.. Chief Executive Officer Apr 22 Sell 150.68 72,365 10,903,958 1,835,902 04/22/21
Eltoukhy Helmy Chief Executive Offi.. Chief Executive Officer Apr 14 Sell 155.52 239,649 37,270,212 2,167,429 04/14/21
MERESMAN STANLEY J Director Director Apr 14 Option 5.94 4,934 29,308 8,993 04/14/21
MERESMAN STANLEY J Director Director Apr 14 Sell 154.28 4,934 761,218 4,059 04/14/21
Eltoukhy Helmy Chief Executive Offi.. Chief Executive Officer Apr 09 Sell 159.1 220,685 35,110,984 2,407,078 04/09/21
CLARK IAN T Director Director Mar 29 Option 4.18 538 2,249 5,181 03/29/21
CLARK IAN T Director Director Mar 29 Sell 132.09 538 71,064 4,643 03/29/21
CLARK IAN T Director Director Mar 01 Option 4.18 538 2,249 5,181 03/01/21
CLARK IAN T Director Director Mar 01 Sell 154 538 82,852 4,643 03/01/21
Talasaz AmirAli Chairman, President.. Chairman, President and COO Feb 12 Sell 168.73 6,613 1,115,811 470,800 02/12/21
Talasaz AmirAli Chairman, President.. Chairman, President and COO Feb 12 Sell 162.35 292,773 47,531,697 477,413 02/12/21
MERESMAN STANLEY J Director Director Feb 12 Option 5.94 4,934 29,308 8,993 02/12/21
MERESMAN STANLEY J Director Director Feb 12 Sell 162.71 4,934 802,811 4,059 02/12/21
Talasaz AmirAli Chairman, President.. Chairman, President and COO Feb 09 Sell 161.95 454,650 73,630,568 509,631 02/09/21
Talasaz AmirAli Chairman, President.. Chairman, President and COO Feb 05 Sell 158.88 142,400 22,624,512 568,601 02/05/21
Talasaz AmirAli Chairman, President.. Chairman, President and COO Feb 03 Sell 156.01 260,404 40,625,628 587,033 02/03/21
Eltoukhy Helmy Chief Executive Offi.. Chief Executive Officer Jan 26 Sell 159.03 160,886 25,585,701 2,627,763 01/26/21
Eltoukhy Helmy Chief Executive Offi.. Chief Executive Officer Jan 21 Sell 163.08 489,114 79,764,711 2,788,649 01/21/21
Eltoukhy Helmy Chief Executive Offi.. Chief Executive Officer Jan 19 Sell 158.57 150,000 23,785,500 514,020 01/19/21